For MSLs in particular, credibility is built through scientific depth, integrity, responsiveness, and the ability to communicate complex data in a clinically meaningful way.

Scientific Exchange: The Foundation of MSL Excellence

Scientific exchange is one of the most important responsibilities of an MSL. It involves fair-balanced, non-promotional, evidence-based discussion with healthcare professionals and other external stakeholders. The goal is not to influence prescribing behavior, but to advance scientific understanding and support informed clinical decision-making.

Effective scientific exchange requires more than knowing the data. MSLs must understand the clinical context, unmet needs, treatment pathways, guideline recommendations, emerging evidence, and stakeholder priorities. A strong scientific discussion should be tailored to the knowledge level and interests of the healthcare professional while remaining grounded in approved materials, peer-reviewed data, and appropriate medical response frameworks.

For example, when discussing a new therapy in oncology, an MSL may need to explain not only the primary endpoint of a pivotal trial but also subgroup analyses, safety considerations, biomarker relevance, sequencing questions, and how the data compare with evolving standards of care. The discussion should clearly distinguish between approved information, investigational data, and areas where evidence remains uncertain.

Best Practices for KOL Engagement

KOL engagement is a central activity in medical affairs, but it must be conducted thoughtfully, ethically, and strategically. The strongest KOL relationships are based on scientific credibility, mutual respect, transparency, and long-term value.

A best-practice approach begins with clear stakeholder identification. Not all influential experts have the same role. Some may be clinical trial investigators, guideline contributors, publication authors, digital opinion leaders, regional experts, or specialists with deep experience treating specific patient populations. Understanding each stakeholder’s expertise and interests allows medical affairs teams to tailor engagement appropriately.

Before engaging a KOL, MSLs should prepare by reviewing recent publications, congress presentations, clinical trial involvement, treatment philosophy, and known areas of research interest. During the interaction, the MSL should prioritize active listening and scientific dialogue rather than delivering a scripted presentation. After the interaction, insights should be documented accurately and compliantly, focusing on scientific themes rather than promotional interpretations.

High-quality KOL engagement often includes:

• Discussing emerging evidence and clinical practice gaps
• Seeking expert perspective on unmet medical needs
• Understanding barriers to guideline implementation
• Exploring interest in research collaborations, when appropriate
• Supporting scientific education through compliant, non-promotional channels

A practical example would be an MSL meeting with a regional cardiology expert to discuss real-world challenges in managing patients with heart failure. The KOL may share that adherence issues, access barriers, and gaps in multidisciplinary care are limiting patient outcomes. These insights can help medical affairs identify educational needs, inform evidence-generation priorities, and support cross-functional strategy while maintaining appropriate compliance boundaries.

Medical Insights: Turning Field Intelligence Into Strategy

One of the most valuable contributions of field medical teams is the collection and interpretation of medical insights. Insights are not simply meeting notes or isolated opinions. They are meaningful observations from external stakeholders that may reveal patterns, unmet needs, data gaps, or changes in clinical practice.

A strong insight is specific, evidence-relevant, and actionable. For example, “Several community oncologists are uncertain how to interpret minimal residual disease data in routine practice” is more useful than “Physicians have questions about biomarkers.” The first statement identifies a defined educational gap and may guide future medical education, advisory board topics, or evidence-generation planning.

Medical affairs teams should establish a structured process for insight collection, analysis, and communication. This includes defining what qualifies as an insight, using consistent documentation standards, aggregating themes across regions, and sharing findings with appropriate internal stakeholders such as clinical development, regulatory, market access, and medical strategy teams.

Importantly, insight collection must remain non-promotional and compliant. MSLs should not solicit off-label use for commercial purposes, gather competitive intelligence inappropriately, or document stakeholder comments in a way that implies commercial intent.

Evidence Generation and Real-World Evidence

Medical affairs increasingly contributes to evidence-generation strategy, particularly after regulatory approval. While randomized controlled trials remain the foundation for demonstrating safety and efficacy, real-world evidence can help answer important questions about treatment patterns, adherence, patient outcomes, healthcare resource utilization, and effectiveness in broader populations.

Evidence-generation activities may include observational studies, registries, chart reviews, pragmatic trials, health economics and outcomes research, and investigator-sponsored research. These initiatives can be especially valuable when clinicians need data in populations underrepresented in pivotal trials, such as older adults, patients with comorbidities, or individuals from diverse racial and ethnic backgrounds.

MSLs may support evidence generation by identifying research interests among external experts, communicating the company’s areas of scientific interest, and facilitating appropriate submission processes for investigator-sponsored studies. They must avoid promising support, influencing study design for promotional purposes, or using research funding as a means to build relationships.

A compliant evidence-generation approach should be scientifically justified, documented, reviewed through appropriate governance, and aligned with patient care needs and medical strategy.

Publication Planning and Good Publication Practice

Publication activities are an essential component of medical affairs. Peer-reviewed publications and congress presentations ensure that clinical and scientific data are disseminated transparently and responsibly to the medical community.

Publication planning should follow Good Publication Practice principles, including integrity, transparency, appropriate authorship, timely disclosure of results, and clear acknowledgment of funding or editorial support. Authorship should be based on substantial intellectual contribution, drafting or critical review, approval of the final version, and accountability for the work. Guest authorship, ghostwriting, and inappropriate author influence must be avoided.

Medical affairs teams involved in publications should ensure that data are presented accurately and that conclusions are supported by the evidence. Negative, inconclusive, or safety-related findings should not be suppressed. Balanced publication practices reinforce scientific credibility and support informed decision-making by clinicians.

Compliance Considerations for Medical Affairs and MSLs

Compliance is central to every medical affairs activity. Because medical affairs teams often discuss complex scientific information and interact with influential external experts, clear boundaries are essential.

Key compliance principles include:

• Maintain separation between medical and promotional activities
• Respond to unsolicited off-label questions in a factual, balanced, and non-promotional manner
• Use approved scientific materials and follow internal review processes
• Document interactions accurately and objectively
• Avoid offering anything of value to influence prescribing or recommendations
• Ensure advisory boards and consulting engagements have legitimate scientific objectives and fair market value compensation
• Follow applicable regional requirements, including FDA, EMA, and local regulatory expectations

In the United States, FDA expectations emphasize that manufacturer communications must not be false or misleading and that promotional claims must be consistent with approved labeling. In Europe, EMA-related frameworks and country-specific codes similarly emphasize accuracy, balance, and appropriate scientific communication. Global organizations must also account for local regulations, industry codes, privacy requirements, and company policies.

For MSLs, a common compliance scenario involves receiving an unsolicited question about an investigational use of an approved product. The appropriate response should be reactive, scientifically balanced, and limited to the specific question asked. The MSL should avoid broadening the discussion into promotional territory and should document the exchange according to company procedures.

Cross-Functional Collaboration Without Losing Medical Independence

Medical affairs operates within a broader organizational ecosystem and frequently collaborates with clinical development, regulatory, commercial, market access, patient advocacy, and health economics teams. This collaboration is essential, but medical independence must be preserved.

For example, field medical insights may help clinical development identify gaps in trial design or inform market access teams about evidence needs from payers. Medical affairs may also support commercial colleagues by providing disease state training or scientific context. However, medical teams should not be directed by sales objectives, should not participate in promotional selling, and should not use scientific exchange to drive product uptake.

The most effective organizations establish clear governance, role clarity, and documentation standards. Medical affairs should have a defined strategy aligned with scientific priorities, patient needs, and evidence gaps rather than short-term commercial goals.

Measuring the Impact of Medical Affairs

Traditional activity metrics, such as number of KOL interactions or presentations delivered, are no longer sufficient to demonstrate the value of medical affairs. While activity tracking remains useful, organizations increasingly need to measure quality, outcomes, and strategic impact.

Meaningful medical affairs metrics may include improvements in stakeholder engagement quality, insight generation, evidence-gap closure, publication milestones, scientific share of voice, educational impact, or contribution to clinical development strategy. Qualitative measures are also important, particularly when assessing trust, scientific credibility, and the relevance of medical engagement.

For example, a field medical team supporting a rare disease therapy may measure impact by tracking whether expert insights helped refine diagnostic education, improve referral pathway understanding, or identify barriers to genetic testing. These outcomes are more meaningful than simply counting the number of meetings conducted.

The Importance of Continuous Learning

The scientific environment changes rapidly. New clinical trial data, treatment guidelines, regulatory decisions, biomarkers, digital health tools, and real-world evidence can quickly reshape clinical practice. Medical affairs professionals must therefore commit to continuous learning.

For MSLs, excellence requires staying current not only in therapeutic area science but also in communication skills, compliance standards, data interpretation, health equity, patient perspectives, and healthcare system dynamics. Formal training, peer learning, congress participation, journal clubs, and credentialing programs such as BCMAS may support professional development.

Continuous learning also includes developing soft skills. Strong MSLs are not only scientifically knowledgeable; they are skilled listeners, strategic thinkers, ethical decision-makers, and trusted collaborators.

Practical Case Example: Applying Medical Affairs Strategy

Consider a medical affairs team supporting a newly approved therapy in an immunology indication. Pivotal trial data demonstrate efficacy and safety, but early field insights reveal that clinicians have questions about patient selection, long-term safety monitoring, and positioning relative to established therapies.

A well-structured medical affairs response might include several coordinated actions. The field medical team continues compliant scientific exchange with immunology experts and documents recurring data gaps. The medical strategy team reviews whether additional real-world evidence could address long-term treatment questions. The publications team prioritizes transparent dissemination of subgroup and safety analyses. Medical education colleagues develop non-promotional educational resources on disease burden, treatment pathways, and evidence interpretation.

Throughout this process, the team maintains compliance by ensuring that all communications are scientifically balanced, appropriately reviewed, and clearly separated from promotional activities. The result is a medical strategy that responds to real clinical needs while maintaining integrity and regulatory alignment.

Conclusion

Medical affairs professionals and MSLs are essential to advancing scientific understanding, supporting evidence-based medicine, and ensuring that stakeholder engagement remains credible, compliant, and patient-centered. As the healthcare landscape continues to evolve, the value of medical affairs will increasingly depend on scientific excellence, strategic insight, ethical engagement, and the ability to translate complex data into meaningful clinical dialogue.

By prioritizing high-quality scientific exchange, responsible KOL engagement, rigorous evidence generation, compliant communication, and continuous professional development, medical affairs teams can strengthen their impact across the product lifecycle and contribute meaningfully to better patient outcomes.